WO2015042705A1 - Protéines de fusion se liant au récepteur de l'interleukine 4 et utilisations associées - Google Patents

Protéines de fusion se liant au récepteur de l'interleukine 4 et utilisations associées Download PDF

Info

Publication number
WO2015042705A1
WO2015042705A1 PCT/CA2014/050915 CA2014050915W WO2015042705A1 WO 2015042705 A1 WO2015042705 A1 WO 2015042705A1 CA 2014050915 W CA2014050915 W CA 2014050915W WO 2015042705 A1 WO2015042705 A1 WO 2015042705A1
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
cell
protein
nucleic acid
cells
Prior art date
Application number
PCT/CA2014/050915
Other languages
English (en)
Inventor
Fahar Merchant
Original Assignee
Medicenna Biopharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicenna Biopharma Inc. filed Critical Medicenna Biopharma Inc.
Priority to EP14849368.7A priority Critical patent/EP3049526B1/fr
Priority to CN202310077483.4A priority patent/CN116041551A/zh
Priority to CN201480062147.1A priority patent/CN105722982A/zh
Priority to CA2925417A priority patent/CA2925417C/fr
Priority to US15/024,785 priority patent/US10093708B2/en
Priority to JP2016517533A priority patent/JP6936934B2/ja
Priority to EP21158648.2A priority patent/EP3910061A1/fr
Publication of WO2015042705A1 publication Critical patent/WO2015042705A1/fr
Priority to US16/125,075 priority patent/US11084856B2/en
Priority to US17/397,287 priority patent/US20220048965A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis

Abstract

La présente invention concerne des protéines de fusion se liant au récepteur de l'interleukine 4. Plus spécifiquement, l'invention concerne, en partie, des protéines de fusion qui comprennent une fraction de protéine se liant au récepteur de l'interleukine 4 associée à une fraction de protéine membre de la famille Bcl-2 pro-apoptotique.
PCT/CA2014/050915 2013-09-24 2014-09-24 Protéines de fusion se liant au récepteur de l'interleukine 4 et utilisations associées WO2015042705A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP14849368.7A EP3049526B1 (fr) 2013-09-24 2014-09-24 Protéines de fusion se liant au récepteur de l'interleukine 4 et utilisations associées
CN202310077483.4A CN116041551A (zh) 2013-09-24 2014-09-24 白介素-4受体结合融合蛋白及其应用
CN201480062147.1A CN105722982A (zh) 2013-09-24 2014-09-24 白介素-4受体结合融合蛋白及其应用
CA2925417A CA2925417C (fr) 2013-09-24 2014-09-24 Proteines de fusion se liant au recepteur de l'interleukine 4 et utilisations associees
US15/024,785 US10093708B2 (en) 2013-09-24 2014-09-24 Interleukin-4 receptor-binding fusion proteins and uses thereof
JP2016517533A JP6936934B2 (ja) 2013-09-24 2014-09-24 インターロイキン−４受容体結合融合タンパク質及びその使用
EP21158648.2A EP3910061A1 (fr) 2013-09-24 2014-09-24 Protéines de fusion de liaison au récepteur de l'interleukine-4 et leurs utilisations
US16/125,075 US11084856B2 (en) 2013-09-24 2018-09-07 Interleukin-4 receptor-binding fusion proteins and uses thereof
US17/397,287 US20220048965A1 (en) 2013-09-24 2021-08-09 Interleukin-4 receptor-binding fusion proteins and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361881930P 2013-09-24 2013-09-24
US61/881,930 2013-09-24

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US15/024,785 A-371-Of-International US10093708B2 (en) 2013-09-24 2014-09-24 Interleukin-4 receptor-binding fusion proteins and uses thereof
US16/125,075 Division US11084856B2 (en) 2013-09-24 2018-09-07 Interleukin-4 receptor-binding fusion proteins and uses thereof
US16/125,075 Continuation US11084856B2 (en) 2013-09-24 2018-09-07 Interleukin-4 receptor-binding fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
WO2015042705A1 true WO2015042705A1 (fr) 2015-04-02

Family

ID=52741678

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CA2014/050915 WO2015042705A1 (fr) 2013-09-24 2014-09-24 Protéines de fusion se liant au récepteur de l'interleukine 4 et utilisations associées
PCT/CA2014/050916 WO2015042706A1 (fr) 2013-09-24 2014-09-24 Protéines de fusion de liaison au récepteur de l'interleukine-4 et leurs utilisations

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CA2014/050916 WO2015042706A1 (fr) 2013-09-24 2014-09-24 Protéines de fusion de liaison au récepteur de l'interleukine-4 et leurs utilisations

Country Status (6)

Country Link
US (6) US10093708B2 (fr)
EP (3) EP3910061A1 (fr)
JP (4) JP6936934B2 (fr)
CN (4) CN116041551A (fr)
CA (3) CA2925417C (fr)
WO (2) WO2015042705A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017015630A2 (fr) * 2015-07-23 2017-01-26 Modernatx, Inc. Acides ribonucléiques messagers pour la production de polypeptides de liaison intracellulaires et leurs procédés d'utilisation
WO2017085235A1 (fr) * 2015-11-19 2017-05-26 Universität Basel Administration de protéines basée sur des bactéries
US20180201651A1 (en) * 2015-06-30 2018-07-19 Kyungpook National University Industry-Academic Cooperation Foundation Pharmaceutical composition that is anticancer and suppresses cancer metastasis, containing, as active ingredient, fusion peptide simultaneously targeting cancer cell and tumor associated macrophage
US10889823B2 (en) 2014-05-21 2021-01-12 Universitaet Basel Bacteria-based protein delivery
US11166987B2 (en) 2015-11-19 2021-11-09 Universitaet Basel Virulence attenuated bacteria for treatment of malignant solid tumors
US11518789B2 (en) 2016-12-20 2022-12-06 Universitaet Basel Virulence attenuated bacteria based protein delivery
WO2023170475A3 (fr) * 2022-03-08 2023-11-16 Medicenna Therapeutics, Inc. Utilisations et procédés pour molécules bifonctionnelles de cytokine d'il-2, d'il-13 et d'il-4

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3049445A4 (fr) * 2013-09-24 2017-10-25 Medicenna Therapeutics, Inc. Protéines hybrides de l'interleukine-2 et leurs utilisations
CA2925417C (fr) * 2013-09-24 2023-10-24 Fahar Merchant Proteines de fusion se liant au recepteur de l'interleukine 4 et utilisations associees
WO2017001568A1 (fr) 2015-07-01 2017-01-05 Universitat De Lleida Traitement et prévention de la sclérose latérale amyotrophique
CN109503715B (zh) * 2017-09-15 2023-12-15 科济生物医药（上海）有限公司 Il-4r的融合蛋白及其应用
CN114457024A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达IL-4Rα阻断物的多能干细胞或其衍生物及应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5501959A (en) 1989-01-17 1996-03-26 Alamar Biosciences Laboratory, Inc. Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents
US6011002A (en) 1994-04-08 2000-01-04 The United States Of America As Represented By The Department Of Health And Human Services Circularly permuted ligands and circularly permuted chimeric molecules
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
US20050106148A1 (en) 2000-10-31 2005-05-19 Amgen Inc. Method of treating blood disorders
WO2006074451A2 (fr) * 2005-01-10 2006-07-13 Research Development Foundation Molecules chimeriques ciblees pour la therapie du cancer
WO2009029601A2 (fr) * 2007-08-24 2009-03-05 Regents Of The University Of Minnesota Réactifs de ciblage de récepteurs
WO2010031185A1 (fr) 2008-09-19 2010-03-25 Protox Therapeutics Inc. Traitement de cellules souches cancéreuses à l'aide de protéines cargo ciblées
WO2012054929A2 (fr) 2010-10-22 2012-04-26 Protox Therapeutics Corp. Utilisation d'albumine sérique humaine pour diminuer l'immunogénicité de protéines thérapeutiques
WO2012139112A1 (fr) 2011-04-08 2012-10-11 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Fusions d'ubiquitine pour améliorer l'efficacité de toxines ciblées à action cytosolique

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
AU5010793A (en) 1992-08-21 1994-03-15 Schering Corporation Human interleukin-13
DE4423131A1 (de) 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
US6410046B1 (en) 1996-11-19 2002-06-25 Intrabrain International Nv Administering pharmaceuticals to the mammalian central nervous system
JP4505166B2 (ja) * 1999-09-09 2010-07-21 シェーリング コーポレイション 哺乳動物インターロイキン−１２ｐ４０およびインターロイキンｂ３０、その組成物、抗体、薬学的組成物における使用
CA2386248A1 (fr) 1999-10-06 2001-04-12 The Penn State Research Foundation Mutants il13
CA2404763A1 (fr) 1999-11-11 2001-05-17 Raj K. Puri Modulation de l'activite de il-13 au moyen de molecules il-13 qui sont des antagonistes ou des agonistes de il-13
GB0004016D0 (en) 2000-02-22 2000-04-12 Royal Brompton Hospital Biological material and uses thereof
DE60142479D1 (de) 2000-08-30 2010-08-12 Penn State Res Found Aminosäureaustauschmutanten von interleukin 13
US20030091640A1 (en) 2001-02-08 2003-05-15 Srinivasan Ramanathan Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents
IL159215A0 (en) 2001-06-07 2004-06-01 Wyeth Corp A solution of interleukin-13 and methods utilizing the same
US20040248260A1 (en) 2001-10-26 2004-12-09 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
US20050027110A1 (en) 2003-07-24 2005-02-03 Michael Russell Drug delivery in the nervous system
AU2006347606B2 (en) * 2005-09-09 2012-10-11 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for inhibiting cell death or enhancing cell proliferation
WO2007048019A2 (fr) 2005-10-20 2007-04-26 The Penn State Research Foundation Systeme d'administration d'agents de diagnostic et therapeutiques
WO2008101671A2 (fr) * 2007-02-19 2008-08-28 Apogenix Gmbh PROTÉINES HYBRIDES IL4-Fc
CN102112144A (zh) * 2008-05-16 2011-06-29 拜耳医药保健有限公司 靶向性凝固因子及其使用方法
US20100183545A1 (en) * 2008-10-14 2010-07-22 The United States Of America, As Represented By The Secretary, Targeted cargo protein combination therapy
SG171733A1 (en) * 2008-11-26 2011-07-28 Glaxo Group Ltd Ligands that bind il-13
US20110023680A1 (en) 2009-07-30 2011-02-03 Kuo-Chung Wang Pcb cutter module with detachable cutters
WO2011106779A1 (fr) 2010-02-26 2011-09-01 Aerovance Inc. Utilisation d'antagonistes des récepteurs de la mutiène il-4 modifiée pour traiter la dermatite
EP2850093B1 (fr) * 2012-01-27 2019-01-09 The Board of Trustees of the Leland Stanford Junior University Polypeptides d'il-13 thérapeutiques
CA2925417C (fr) * 2013-09-24 2023-10-24 Fahar Merchant Proteines de fusion se liant au recepteur de l'interleukine 4 et utilisations associees

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5501959A (en) 1989-01-17 1996-03-26 Alamar Biosciences Laboratory, Inc. Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents
US6011002A (en) 1994-04-08 2000-01-04 The United States Of America As Represented By The Department Of Health And Human Services Circularly permuted ligands and circularly permuted chimeric molecules
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
US20050106148A1 (en) 2000-10-31 2005-05-19 Amgen Inc. Method of treating blood disorders
WO2006074451A2 (fr) * 2005-01-10 2006-07-13 Research Development Foundation Molecules chimeriques ciblees pour la therapie du cancer
WO2009029601A2 (fr) * 2007-08-24 2009-03-05 Regents Of The University Of Minnesota Réactifs de ciblage de récepteurs
WO2010031185A1 (fr) 2008-09-19 2010-03-25 Protox Therapeutics Inc. Traitement de cellules souches cancéreuses à l'aide de protéines cargo ciblées
WO2012054929A2 (fr) 2010-10-22 2012-04-26 Protox Therapeutics Corp. Utilisation d'albumine sérique humaine pour diminuer l'immunogénicité de protéines thérapeutiques
WO2012139112A1 (fr) 2011-04-08 2012-10-11 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Fusions d'ubiquitine pour améliorer l'efficacité de toxines ciblées à action cytosolique

Non-Patent Citations (50)

* Cited by examiner, † Cited by third party
Title
"GenBank", Database accession no. CAG46733.1
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1997, JOHN WILEY & SONS
BACHRAN, C. ET AL.: "Anthrax toxin-mediated delivery of the Pseudomonas exotoxin A enzymatic domain to the cytosol of tumor cells via cleavable ubiquitin fusions", MBIO., vol. 4, no. 3, 30 April 2013 (2013-04-30), pages e00201 - 13, XP055145379, DOI: 10.1128/mBio.00201-13
BARLTROP, BIOORG. & MED. CHEM. LETT., vol. 1, 1991, pages 611
BEYER ET AL., BLOOD, vol. 106, 2005, pages 2018 - 2025
BRIGHAM ET AL., AM. J. MED. SCI., vol. 298, 1989, pages 278
CLEARY ET AL., CELL, vol. 47, 1986, pages 19 - 28
CORY ET AL., CANCER COMM., vol. 3, 1991, pages 207 - 12
CREE ET AL., ANTICANCER DRUGS, vol. 6, 1995, pages 398 - 404
CROUCH ET AL., J. IMMUNOL. METH., vol. 160, pages 81 - 8
CURIEL ET AL., NAT. MED., vol. 10, 2004, pages 942 - 949
DIEHN ET AL., J. NATL. CANCER INST., vol. 98, 2006, pages 1755 - 7
FEIGNER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 84, 1987, pages 7413
FIELDS & LANCASTER AM. BIOTECHNOL. LAB., vol. 11, 1993, pages 48 - 50
HENRY ET AL., BIOMACROMOLECULES, vol. 7, no. 8, 2006, pages 2407 - 14
HISKEY, PEPTIDES, vol. 3, 1981, pages 137
ICHIHARA ET AL., CLIN CANCER RES., vol. 9, no. 12, 2003, pages 4404 - 4408
JAVIA ET AL., J. IMMUNOTHER., vol. 26, no. 1, 2003, pages 85 - 93
JUNTTILA ET AL., NATURE CHEMICAL BIOLOGY, vol. 8, 2012, pages 990 - 998
KANGAS ET AL., MED. BIOL., vol. 62, 1984, pages 338 - 43
KITANO ET AL., EURO. J. CLIN. INVESTG., vol. 21, 1991, pages 53 - 58
KREITMANPASTAN, BLOOD, vol. 90, 1997, pages 252 - 259
LASKE ET AL., NATURE MEDICINE, vol. 3, 1997, pages 1362 - 1368
LIYANAGE ET AL., J IMMUNOL., vol. 169, no. 5, 2002, pages 2756 - 2761
LOMONOSOVA, E.G. CHINNADURAI, ONCOGENE, vol. 27, 2009, pages S2 - S19
LUNDIN ET AL., METH. ENZYMOL., vol. 133, 1986, pages 27 - 42
O'BRIEN ET AL., EUR. J. BIOCHEM., vol. 267, 2000, pages 5421 - 5426
ONO ET AL., NEUROSCIENCE LETTERS, vol. 17, 1990, pages 259
PAULL, J. HETEROCYCLIC CHEM., vol. 25, 1988, pages 911
PETTY ET AL., COMPARISON OF J. BIOLUM. CHEMILUM., vol. 10, 1995, pages 29 - 34
REYNOLDS ET AL., CANCER RES., vol. 56, no. 24, 1996, pages 5754 - 5757
RUBIN, BRITISH MED. BULLE., vol. 53, no. 3, 1997, pages 617 - 631
RUBINSTEIN ET AL., J. NATL. CANCER INST., vol. 82, 1999, pages 113 - 118
SAKARIASSEN ET AL., NEOPLASIA, vol. 9, no. 11, 2007, pages 882 - 92
SASADA ET AL., CANCER, vol. 98, no. 5, 2003, pages 1089 - 1099
SHI ET AL., AI ZHENG., vol. 23, no. 5, 2004, pages 597 - 601
SHIMAMURA ET AL., CANCER RES., vol. 67, 2007, pages 9903 - 9912
STAUBINGER ET AL., METHODS IN ENZYMOLOGY, vol. 101, 1983, pages 512
STICKLER ET AL., J. IMMUNOTHERAPY, vol. 23, 2000, pages 654 - 660
THORPE ET AL., NATURE, vol. 271, 1978, pages 752 - 755
TSUJIMOTOCROCE, PROC. NATL. ACAD. SCI. USA, vol. 83, 1986, pages 5214 - 5218
VALLERA, D.A. ET AL.: "Retroviral immunotoxin gene therapy of leukemia in mice using leukemia-specific T cells transduced with an interleukin-3/Bax fusion protein gene", HUM GENE THER., vol. 14, no. 18, 10 December 2003 (2003-12-10), pages 1787 - 1798, XP055335277 *
VIGUIER ET AL., J. IMMUNOL., vol. 173, no. 2, 2004, pages 1444 - 53
WEST ET AL., J. INVESTIGATIVE DERM., vol. 99, 1992, pages 95 - 100
WHITE, GENES DEV., vol. 10, 1996, pages 1 - 15
WOLFF ET AL., SCIENCE, vol. 247, 1990, pages 1465 - 1303
WOO ET AL., CANCER RES., vol. 61, no. 12, 2001, pages 4766 - 72
WU ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, 1988, pages 14621
WU ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 264, 1989, pages 16985
YANG ET AL., CELL, vol. 80, 1995, pages 285 - 291

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10889823B2 (en) 2014-05-21 2021-01-12 Universitaet Basel Bacteria-based protein delivery
US20180201651A1 (en) * 2015-06-30 2018-07-19 Kyungpook National University Industry-Academic Cooperation Foundation Pharmaceutical composition that is anticancer and suppresses cancer metastasis, containing, as active ingredient, fusion peptide simultaneously targeting cancer cell and tumor associated macrophage
WO2017015630A3 (fr) * 2015-07-23 2017-03-30 Modernatx, Inc. Acides ribonucléiques messagers pour la production de polypeptides de liaison intracellulaires et leurs procédés d'utilisation
WO2017015630A2 (fr) * 2015-07-23 2017-01-26 Modernatx, Inc. Acides ribonucléiques messagers pour la production de polypeptides de liaison intracellulaires et leurs procédés d'utilisation
US11166987B2 (en) 2015-11-19 2021-11-09 Universitaet Basel Virulence attenuated bacteria for treatment of malignant solid tumors
CN108884466A (zh) * 2015-11-19 2018-11-23 巴塞尔大学 基于细菌的蛋白递送
WO2017085235A1 (fr) * 2015-11-19 2017-05-26 Universität Basel Administration de protéines basée sur des bactéries
EA039922B1 (ru) * 2015-11-19 2022-03-28 Университет Базель Доставка белка бактериями
CN108884466B (zh) * 2015-11-19 2022-06-03 巴塞尔大学 基于细菌的蛋白递送
US11702663B2 (en) 2015-11-19 2023-07-18 Universität Basel Bacteria-based protein delivery
IL259050B1 (en) * 2015-11-19 2023-11-01 Univ Basel Providing bacteria-based protein
IL259050B2 (en) * 2015-11-19 2024-03-01 Univ Basel Providing bacteria-based protein
US11518789B2 (en) 2016-12-20 2022-12-06 Universitaet Basel Virulence attenuated bacteria based protein delivery
WO2023170475A3 (fr) * 2022-03-08 2023-11-16 Medicenna Therapeutics, Inc. Utilisations et procédés pour molécules bifonctionnelles de cytokine d'il-2, d'il-13 et d'il-4

Also Published As

Publication number Publication date
CN113563478A (zh) 2021-10-29
CN105722982A (zh) 2016-06-29
CN116041551A (zh) 2023-05-02
US20160237135A1 (en) 2016-08-18
EP3049525A1 (fr) 2016-08-03
JP2016533343A (ja) 2016-10-27
JP6936934B2 (ja) 2021-09-22
US11352402B2 (en) 2022-06-07
JP2023052641A (ja) 2023-04-11
US11084856B2 (en) 2021-08-10
JP6661530B2 (ja) 2020-03-11
JP2020010701A (ja) 2020-01-23
JP2016533166A (ja) 2016-10-27
CA2925417C (fr) 2023-10-24
US20160215035A1 (en) 2016-07-28
US20220048965A1 (en) 2022-02-17
EP3049526A1 (fr) 2016-08-03
US10106592B2 (en) 2018-10-23
EP3049526A4 (fr) 2017-10-11
US20190100567A1 (en) 2019-04-04
US20190100568A1 (en) 2019-04-04
WO2015042706A1 (fr) 2015-04-02
CA3180148A1 (fr) 2015-04-02
EP3049525A4 (fr) 2017-05-03
US10093708B2 (en) 2018-10-09
CA2930074A1 (fr) 2015-04-02
US20220372096A1 (en) 2022-11-24
CA2925417A1 (fr) 2015-04-02
CN105764926A (zh) 2016-07-13
EP3049526B1 (fr) 2021-02-24
EP3910061A1 (fr) 2021-11-17

Similar Documents

Publication Publication Date Title
US11084856B2 (en) Interleukin-4 receptor-binding fusion proteins and uses thereof
US11680090B2 (en) Interleukin-2 fusion proteins and uses thereof
KR102102789B1 (ko) 디스인테그린 변이체 및 이의 약학적 용도
HUE032576T2 (en) Anti-cancer fusion protein
US8822421B2 (en) E2F as a target of hormone refractory prostate cancer
KR102348838B1 (ko) 트레일 트라이머와 암표적 펩타이드를 멀티디스플레이하는 페리틴 나노케이지 및 이의 항암제로서의 용도
CA3096978A1 (fr) Compositions destinees a etre utilisees dans la lyse de cellules cancereuses selectives
US11912747B2 (en) Chimeric proteins for targeting dsRNA
US20180353627A1 (en) Radiolabeled disintegrins as brachytherapy agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14849368

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2016517533

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2925417

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15024785

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2014849368

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014849368

Country of ref document: EP